Federated Hermes Inc. Reduces Position in Dynavax Technologies Co. (NASDAQ:DVAX)

Federated Hermes Inc. decreased its holdings in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 99.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,000 shares of the biopharmaceutical company's stock after selling 5,600,200 shares during the quarter. Federated Hermes Inc.'s holdings in Dynavax Technologies were worth $102,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. grew its stake in Dynavax Technologies by 2.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,155,080 shares of the biopharmaceutical company's stock worth $14,750,000 after purchasing an additional 32,347 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Dynavax Technologies by 4.4% in the 4th quarter. Bank of New York Mellon Corp now owns 931,328 shares of the biopharmaceutical company's stock worth $11,893,000 after acquiring an additional 39,513 shares in the last quarter. Nordea Investment Management AB lifted its position in Dynavax Technologies by 42.7% during the 4th quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company's stock valued at $10,034,000 after acquiring an additional 232,690 shares during the period. Trexquant Investment LP lifted its position in Dynavax Technologies by 48.7% during the 4th quarter. Trexquant Investment LP now owns 776,397 shares of the biopharmaceutical company's stock valued at $9,915,000 after acquiring an additional 254,405 shares during the period. Finally, Peregrine Capital Management LLC boosted its stake in Dynavax Technologies by 1.8% during the fourth quarter. Peregrine Capital Management LLC now owns 654,620 shares of the biopharmaceutical company's stock worth $8,359,000 after acquiring an additional 11,687 shares in the last quarter. Institutional investors own 96.96% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. William Blair reissued an "outperform" rating on shares of Dynavax Technologies in a research report on Friday, February 21st. HC Wainwright reissued a "buy" rating and set a $31.00 price target on shares of Dynavax Technologies in a research report on Friday, February 21st. StockNews.com raised Dynavax Technologies from a "hold" rating to a "buy" rating in a research report on Monday, February 24th. Finally, The Goldman Sachs Group reduced their target price on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating for the company in a report on Thursday, April 17th.

Dynavax Technologies Price Performance

Shares of DVAX traded up $0.06 during trading hours on Wednesday, reaching $10.78. 1,638,389 shares of the stock traded hands, compared to its average volume of 2,188,338. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. The company's 50-day moving average price is $12.90 and its two-hundred day moving average price is $12.56. The company has a market cap of $1.34 billion, a P/E ratio of 59.80 and a beta of 1.26. Dynavax Technologies Co. has a 52-week low of $9.74 and a 52-week high of $14.63.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last released its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, hitting the consensus estimate of $0.05. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. The firm had revenue of $72.03 million for the quarter, compared to the consensus estimate of $72.70 million. On average, analysts anticipate that Dynavax Technologies Co. will post 0.32 earnings per share for the current year.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.